Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 125Myelodysplastic Syndromes 120Precursor Cell Lymphoblastic Leukemia-Lymphoma 107Leukemia 86Hodgkin Disease 81Leukemia, Lymphocytic, Chronic, B-Cell 78Lymphoma 76Multiple Myeloma 75Lymphoma, Non-Hodgkin 75Myeloproliferative Disorders 57Graft vs Host Disease 55Lymphoma, Follicular 54Lymphoma, Mantle-Cell 50Lymphoma, Large B-Cell, Diffuse 50Leukemia, Myeloid, Accelerated Phase 50Leukemia, Myelomonocytic, Chronic 48Congenital Abnormalities 48Leukemia, Myelogenous, Chronic, BCR-ABL Positive 47Hematologic Neoplasms 45Lymphoma, B-Cell, Marginal Zone 44Leukemia, Myeloid, Chronic-Phase 44Burkitt Lymphoma 42Primary Myelofibrosis 41Blast Crisis 39Neoplasms, Plasma Cell 38Lymphoma, Large-Cell, Immunoblastic 34Waldenstrom Macroglobulinemia 26Myelodysplastic-Myeloproliferative Diseases 25Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25Anemia, Refractory, with Excess of Blasts 24

Interventions

gamma-Globulins 1Tacrolimus 1Salpingo-oophorectomy 1Magnetic Resonance Imaging 1Immunologic Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraneoplastic Syndromes × Tacrolimus × Clear all
NCT00378326 2023-09-18

Immunotherapy of the Paraneoplastic Syndromes

Rockefeller University

Phase NA Completed
26 enrolled 6 charts

Paraneoplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡